More on AXSM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $239.62 |
|
|||
| Open | $239.00 | ||||
| 52 Wk High | $15.74 | ||||
| 52 Wk Low | $5.37 | ||||
| Day High | $244.60 | ||||
| Day Low | $237.00 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 500,365 | ||||
- BMO Capital Starts Axsome Therapeutics (AXSM) at Outperform
- H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
- Form 8-K Axsome Therapeutics, For: Jul 15
- FDA accepts Axsome drug application for cataplexy treatment
- Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
- Piper Sandler Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
- Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
- H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
- Axsome Therapeutics (AXSM) PT Raised to $304 at RBC Capital
- Axsome starts Phase 3 trial of solriamfetol in children with ADHD
Entities mentioned with AXSM
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- S1 | View Related Stories »
- Show More...
